Business
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board\nPR Newswire\nORLANDO, Fla., Sept. 21, 2016\n\n\n\nORLANDO, Fla., Sept. 21, 2016 /PRNewswire-USNewswire/ -- Immune Therapeutics, Inc. (OTCQB: IMUN), a clinical-stage pharmaceutical company focused on the commercialization and development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, today announces the appointment of two new members to its Medical and Clinical Advisory Board comprised of: Joseph M. Chalil, MD and Mak Jawadekar, Ph.D., join Clifford A. Selsky, Ph.D., MD, Jill Smith MD, Terry Grossman MD, and Nicholas P. Plotnikoff, Ph.D.\n\n\"The experts on our Advisory Board will work closely with the management team to advance the Company's portfolio of novel immunotherapies. They join us at a critical time, as we are hoping to enter into a Phase 2b/3 clinical trial of IRT-013 for Crohn's Disease in the U.S. and HIV and Cancer in Africa,\" said Noreen Griffin President and Chief Executive Officer of Immune Therapeutics. \"This team of accomplished Medical Scientific and clinical leaders complements the expertise of the management team and will collaborate with us on our goal of bringing these new and critical therapies to patients while addressing the issue of affordable non-toxic therapies – a growing global healthcare crisis.\"\n\nInitial Appointments to Immune Therapeutics, Inc. Medical Scientific and Clinical Advisory Board\n\nDr. Chalil MD, MBA, FACHE is Associate Director, Health Science Executives of Boehringer Ingelheim, the world's largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, the Company operates globally in more than 50 countries. In 2012, Boehringer Ingelheim achieved net sales of 19.1 billion (USD); R&D expenditure in the business area of prescription medicines reached a quarter of its net sa...